This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Activity
    • Table of Contents
  • Post-Test
  • Evaluation
  • Claim Credit
Comprehensive Cardiology Seminar and Board Review Course Recently Added

Comprehensive Cardiology Seminar and Board Review Course

This activity carries a fee of $599.00 to review the content and receive credit.

Format

Board Review

Time to Complete

29.25 hours

Released

November 1, 2015

Expires

November 1, 2017

Maximum Credits

29.25 / AMA PRA Category 1 Credit(s)TM

Accredited Provider


This activity is provided by the NYU Post-Graduate Medical School

Commercial Supporter

There is no commercial support for this activity.

Program Description

The NYU Comprehensive Cardiology Seminar and Board Review provides an intensive and comprehensive review of cardiovascular medicine. The program focuses on current guidelines and appropriate use criteria in general clinical cardiology, clinical cardiac electrophysiology, invasive cardiology, cardiovascular prevention and cardiovascular genetics. In addition to thematic lectures, the program includes review sessions, case-based questions, and a review of images in cardiology and electrocardiograms. The program also includes presentations on changes in the healthcare system and their potential impact on the practice of evidence-based quality cardiovascular medicine. This course is of particular value to those preparing for the Board Certification exam. There is supplementary content that includes practice sessions on test-taking skills and a review of images in cardiology and electrocardiograms similar to the materials tested on the Board Examination. A full range of educational tools, including self-assessment activities, are embedded within the didactic lectures. Sample multiple-choice questions are included in each presentation to help participants assess their own knowledge and assist those who are preparing for their Board Exam.

Target Audience

The potential audience includes:

  • Practicing cardiologists seeking continuing medical education and a knowledge update
  • Practicing cardiologists preparing for Board Certification or Recertification
  • Fellows preparing for the Board Certification Examination

Statement of Need

Progress in interventional cardiology technology and technique has rapidly accelerated in recent years. Depending on the training and skill of the cardiologist, as well as the quality of available imaging and catheterization equipment, the quality of care for patients with structural heart diseases can vary markedly. Paradoxically, the very rapid advances in technology that make interventional cardiology an increasingly effective subspecialty creates an inherent gap in knowledge for practicing cardiologists. There is a need to close this gap in quality cardiovascular disease management so that interventions that represent state-of-the-art care are implemented. Management of heart failure requires a multimodal approach. It involves a combination of lifestyle modifications, medications, and possibly the use of devices or surgery. There is significant evidence of a practice gap in the treatment of congestive heart failure, particularly the underuse of β-blockers and aldosterone antagonists, which have been shown to provide mortality benefit. The science of arrhythmia is central to cardiology. Atrial fibrillation is the most common form of arrhythmia. About 2.5 million Americans have atrial fibrillation. As the population ages, it is becoming more common: 2 to 3 percent of 60-year-olds have atrial fibrillation, but the rate rises to 12 percent for 80-year-olds. Once viewed as a nuisance, not necessarily something that required aggressive intervention, atrial fibrillation is now seen as a major risk factor for stroke, and it's clear that atrial fibrillation plays a role in stroke and is a quality-of-life problem. Medication has long been the mainstay of treatment for atrial fibrillation; however, several studies show that its effectiveness is limited. Cardiologists now perform surgical ablations where the errant electrical signals originate. There are different ablation techniques being used and there is a need to recognize the comparative effectiveness and the risks possible with each approach. There is also a need for clinicians to be better able to evaluate clinical situations where ablation may be a first-line treatment for atrial fibrillation rather than an option for patients who don’t improve after drug therapy. Proper selection of noninvasive testing remains a constantly evolving field. Newer types of tests are constantly being introduced into the field, creating a gap in the clinical practice of many cardiologists.

Clinicians need to be updated on these newer diagnostic tools and find the proper clinical situations for their use. Prevention of cardiovascular disease is one of the major accomplishments of the past 60 years. The use of lipid-lowering and antihypertensive medications has proven to be highly effective. To prevent stroke, doctors often prescribe a range of blood thinners. There are considerable differences in the clinical effects of each class of drugs, based on their mechanism of action. Cardiologists need to be expert in the development of effective treatment regimens. This expertise derives from a comprehensive knowledge of clinical trial results as well as an understanding of the design of these studies and the variables they address.

Educational Objectives

After participating in this activity, clinicians should be able to:

  • Outline updated guidelines relative to interventional cardiology
  • Describe the latest technological advances in interventional cardiology and implement them appropriately to optimize patient outcomes
  • Evaluate newer medications to treat CHF and prescribe appropriately to ensure patient safety
  • Review the currently available options of therapy and utilize newer modalities such as ablation, atrial closure devices, and newer anticoagulation regimens for optimal patient outcomes
  • Evaluate the newer noninvasive tests available to diagnose and prognosticate cardiovascular disease
  • Describe the clinical effects of each class of anticoagulants and prescribe appropriately to prevent stroke or minimize untoward outcomes

Program Topics

Introduction to the Certifying Examination — Format, Questions, Relevance, Test-Taking Tricks
Steven M. Kobren, MD

Cardiovascular Physical Examination
Steven M. Kobren, MD

Cardiovascular Physiology
Adam Skolnick, MD

Peripheral Arterial Disease — Part 1
Michael J. Attubato, MD

Biostatistics — How Do We Interpret the Literature?
Harmony Reynolds, MD

Anticoagulation and Antiplatelet Therapy — Working Through the Maze
Jeffrey S. Berger, MD, MS

Chronic Coronary Artery Disease Management— State-of-the-Art Management
Sripal Bangalore, MD, MHA

Genetics and Heart Disease
Glenn I. Fishman, MD

Pericardial Disease
Muhamed Saric, MD, PhD, MPA

Diastolic Dysfunction — Diagnosis and Management
Muhamed Saric, MD, PhD, MPA

Hypertension and Renovascular Disease
Arthur Z. Schwartzbard, MD

Hemodynamics in the Catheterization Laboratory
James Slater, MD

EKGs — What You Need to Know for the Boards
Jeffrey Lorin, MD

Questions — Board-Type Questions with Detailed Answers
John T. Coppola, MD, MS

Cardiomyopathy — Trends in Diagnosis and Management
Mark V. Sherrid, MD

Ventricular Remodeling — Mechanisms and Management
Stuart D. Katz, MD

Systolic Dysfunction
Stuart D. Katz, MD

Advanced Heart Failure — Device Therapy, Surgery, Transplant
Alex Reyentovich, MD

Pulmonary Hypertension
Alex Reyentovich, MD

Peripheral Arterial Disease — Part 2
Michael J. Attubato, MD

Coronary Physiology and Endothelial Function
Steven P. Sedlis, MD

Emergency Cardiac Care
Robert O. Roswell, MD

Non-Invasive Testing — Who, Why, and Which Test?
Lawrence Phillips, MD

Revascularization — Role of Invasive Testing and What Do We Do with the Results
John T. Coppola, MD, MS

Primary and Secondary Prevention of Cardiovascular Disease
Howard S. Weintraub, MD

Venous Thromboembolic and Lymphatic Disease
Ricardo J. Benenstein, MD

Images — Review of Images Likely to Appear on the Boards
John T. Coppola, MD, MS, and Robert Donnino, MD

Questions — Board-Type Questions with Detailed Answers
John T. Coppola, MD, MS

ACS Management
Norma M. Keller, MD

NSTEMI — Diagnosis and Management
Jeffrey S. Berger, MD, MS

Reperfusion Strategies — Who Gets What
Louai Razzouk, MD, MPH

STEMI — Diagnosis and Management
Judith S. Hochman, MD

Aortic Insufficiency and Aortic Stenosis
Barry P. Rosenzweig, MD

Mitral Regurgitation and Mitral Stenosis
Barry P. Rosenzweig, MD

Valvular Hemodynamics — Review of Echocardiographic Evaluation
Muhamed Saric, MD, PhD, MPA

Prosthetic Heart Valves
Muhamed Saric, MD, PhD, MPA

Congenital Heart Disease for the Boards
Catherine R. Weinberg, MD

Electrophysiology and Drug Therapy
David S. Park, MD, PhD

Intracardiac Electrocardiograms — How Do We Read Them and What Do They Mean?
David S. Park, MD, PhD

Mini Board Examination — Q&A Panel Discussion
Steven M. Kobren, MD

Channelopathies — Clinical Relevance for the Boards
Steven J. Fowler, MD

Pacemakers — Patient Selection and Evaluation of the Device
Charles J. Love, MD

Atrial Arrhythmias
Douglas S. Holmes, MD

Atrial Fibrillation
Larry A. Chinitz, MD

Ventricular Arrhythmia
Larry A. Chinitz, MD

ICD Device Therapy — Patient Selection and Evaluation of the Device
Charles J. Love, MD

Syncope — Guideline-Based Evaluation and Management
William R. Slater, MD

Infective Endocarditis
Barry P. Rosenzweig, MD

Pre-Op and Management of Cardiac Patients for Non-Cardiac Surgery
William R. Slater, MD

Diabetes and the Heart
Howard S. Weintraub, MD

Pregnancy and Heart Disease
Catherine R. Weinberg, MD

Faculty

COURSE DIRECTORS:
John T. Coppola, MD, MS
Clinical Assistant Professor of Medicine

Glenn I. Fishman, MD
William Goldring Professor of Medicine and Professor of Neuroscience, Physiology, Biochemistry, and Molecular Pharmacology

Steven M. Kobren, MD
Clinical Associate Professor of Medicine

FACULTY:
Michael J. Attubato, MD
Associate Professor of Medicine

Sripal Bangalore, MD, MHA
Associate Professor of Medicine

Ricardo J. Benenstein, MD
Assistant Professor of Medicine

Jeffrey S. Berger, MD, MS
Associate Professor of Medicine and Surgery

Larry A. Chinitz, MD
Benjamin and Kenneth Coyle, Sr., Family Professor of Medicine and Cardiac Electrophysiology

Robert Donnino, MD
Assistant Professor of Medicine and Radiology

Steven J. Fowler, MD
Assistant Professor of Medicine

Judith S. Hochman, MD
Harold Snyder Family Professor of Medicine

Douglas S. Holmes, MD
Assistant Professor of Medicine

Stuart D. Katz, MD
Helen L. and Martin S. Kimmel Professor of Advanced Cardiac Therapeutics

Norma M. Keller, MD
Assistant Professor of Medicine

Jeffrey Lorin, MD
Assistant Professor of Medicine

Charles J. Love, MD
Professor of Medicine

David S. Park, MD, PhD
Assistant Professor of Medicine

Lawrence Phillips, MD
Assistant Professor of Medicine

Louai Razzouk, MD, MPH
Instructor of Medicine

Alex Reyentovich, MD
Assistant Professor of Medicine

Harmony Reynolds, MD
Saul J. Farber Assistant Professor of Medicine

Barry P. Rosenzweig, MD
Associate Professor of Medicine

Robert O. Roswell, MD
Assistant Professor of Medicine

Muhamed Saric, MD, PhD, MPA
Associate Professor of Medicine

Arthur Z. Schwartzbard, MD
Assistant Professor of Medicine

Steven P. Sedlis, MD
Associate Professor of Medicine

Mark V. Sherrid, MD
Professor of Medicine

Adam Skolnick, MD
Associate Professor of Medicine

James Slater, MD
The Robert and Marc Bell Professor of Cardiology

William R. Slater, MD
Associate Professor of Medicine

Catherine R. Weinberg, MD
Clinical Instructor of Medicine

Howard S. Weintraub, MD
Clinical Professor of Medicine

Credit

29.25

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

The NYU Post-Graduate Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

The NYU Post-Graduate Medical School designates this enduring material for a maximum of 29.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

To receive up to 29.25 CME credits, view all of the presentations, which should take 29.25 hours of your time.

To obtain credit, a score of 70% or better is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test survey, and have received your digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

Disclosure Statement

The NYU Post-Graduate Medical School adheres to ACCME accreditation requirements and policies, including the Standards for Commercial Support regarding industry support of continuing medical education. In order to resolve any identified conflicts of interest, disclosure information is provided during the planning process to ensure resolution of any identified conflicts. Disclosure of faculty and commercial relationships, as well as the discussion of unlabeled or unapproved use of any drug, device or procedure by the faculty, are fully noted below as well as in the course syllabus.

Faculty and Planner Disclosures

Michael J. Attubato, MD, reports no relevant financial relationships.

Sripal Bangalore, MD, MHA, reports no relevant financial relationships.

Ricardo J. Benenstein, MD, reports no relevant financial relationships.

Jeffrey S. Berger, MD, MS, reports no relevant financial relationships.

Larry A. Chinitz, MD, serves as a consultant to Biosense Webster and St. Jude Medical, Inc.

John T. Coppola, MD, MS, reports no relevant financial relationships.

Robert Donnino, MD, reports no relevant financial relationships.

Glenn I. Fishman, MD, reports no relevant financial relationships.

Steven J. Fowler, MD, reports no relevant financial relationships.

Judith S. Hochman, MD, reports no relevant financial relationships.

Douglas S. Holmes, MD, reports no relevant financial relationships.

Stuart D. Katz, MD, serves as a consultant to and is on the speakers’ bureaus of Amgen, Inc., and Novartis Pharmaceuticals Corporation.

Norma M. Keller, MD, reports no relevant financial relationships.

Steven M. Kobren, MD, reports no relevant financial relationships.

Jeffrey Lorin, MD, reports no relevant financial relationships.

Charles J. Love, MD, reports no relevant financial relationships.

David S. Park, MD, PhD, reports no relevant financial relationships.

Lawrence Phillips, MD, reports no relevant financial relationships.

Louai Razzouk, MD, MPH, reports no relevant financial relationships.

Alex Reyentovich, MD, reports no relevant financial relationships.

Harmony Reynolds, MD, reports no relevant financial relationships.

Barry P. Rosenzweig, MD, reports no relevant financial relationships.

Robert O. Roswell, MD, reports no relevant financial relationships.

Muhamed Saric, MD, PhD, MPA, reports no relevant financial relationships.

Arthur Z. Schwartzbard, MD, reports no relevant financial relationships.

Steven P. Sedlis, MD, reports no relevant financial relationships.

Mark V. Sherrid, MD, reports no relevant financial relationships. Dr. Sherrid’s presentation includes discussion of the unlabeled or unapproved use of a drug, device or procedure; ie, all pharmacotherapy for hypertrophic cardiomyopathy is given off-label—beta blockade, verapamil, disopyramide.

Adam Skolnick, MD, reports no relevant financial relationships.

James Slater, MD, reports no relevant financial relationships.

William R. Slater, MD, reports no relevant financial relationships.

Catherine R. Weinberg, MD, reports no relevant financial relationships.

Howard S. Weintraub, MD, serves as a consultant to and receives research support from Amarin Pharma, Inc. He serves on the speakers’ bureau of Kowa Pharmaceuticals, Inc.

The independent reviewer of this activity reports no relevant financial relationships.


Planner Disclosures:
Thomas S. Riles, MD – Planner – reports no relevant financial relationships.

Joann M. Carpana – Planner – reports no relevant financial relationships.

Danielle Milbauer, MBA – Planner – reports no relevant financial relationships.

Privacy Policy

Copyright

Copyright© 2015, 2016
NYU Post-Graduate Medical School.
All rights reserved.

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Back to top